The London Life Sciences team advised Inflazome on its acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) for an upfront consideration of €380 million. The shareholders of Inflazome, a Dublin-based biotech company leading in the development of inflammasome inhibitors, will also be eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones. Inflazome is backed by leading investors including Forbion, Longitude Capital, Fountain Healthcare Partners and Novartis Venture Fund.
The deal further consolidates Goodwin’s position as the go-to firm for European biotech M&A, following its recent role advising KaNDy Therapeutics in its sale to Bayer in one of the largest private European biotech exits in the past 12 months.
The Goodwin team on the Inflazome matter was led by Andrew Harrow and Graham Defries and included Lucy Thomas and Zena Hadjiargyrou (Life Sciences), Rob Young and Amy Francis (Tax), Paul Jin and Matthew Wheatley (Antitrust) and Mark Smith (Finance).
For additional details, please read the press release.